Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Income: 2014-2024

Historic Non Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$20.7 million.

  • Spyre Therapeutics' Non Operating Income rose 343.09% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.9 million, marking a year-over-year increase of 319.64%. This contributed to the annual value of -$20.7 million for FY2024, which is 78.54% up from last year.
  • Spyre Therapeutics' Non Operating Income amounted to -$20.7 million in FY2024, which was up 78.54% from -$96.5 million recorded in FY2023.
  • Spyre Therapeutics' Non Operating Income's 5-year high stood at $830,000 during FY2022, with a 5-year trough of -$96.5 million in FY2023.
  • In the last 3 years, Spyre Therapeutics' Non Operating Income had a median value of -$20.7 million in 2024 and averaged -$38.8 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Non Operating Income soared by 780.33% in 2022, and later slumped by 11,728.07% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Non Operating Income (Yearly) stood at $588,000 in 2020, then crashed by 120.75% to -$122,000 in 2021, then skyrocketed by 780.33% to $830,000 in 2022, then crashed by 11,728.07% to -$96.5 million in 2023, then spiked by 78.54% to -$20.7 million in 2024.